Lee's Pharmaceutical Acquires Staccato One Breath Technology and Global Rights to Alprazolam

Reuters

2025/12/09

Lee's Pharmaceutical Acquires Staccato One Breath Technology and Global Rights to Alprazolam

Lee's Pharmaceutical Holdings Limited is acquiring the Staccato® One Breath Technology® (OBT®) platform and related assets, including global rights as licensor and manufacturer for Staccato® alprazolam, as part of an expanded partnership with UCB. The Staccato® OBT® platform is a proprietary inhalation technology with applications in central nervous system and neurodegenerative disorders, already validated by the approved product Adasuve® and several late-stage development programs. This transaction will also integrate two Phase 2 clinical-stage CNS assets targeting Parkinson's disease and Cyclic Vomiting Syndrome into Lee's Pharm's portfolio. Upon completion, Lee's Pharm and its partner NPI stand to receive up to US$60.5 million in milestone payments, as well as tiered royalties and manufacturing revenue from global sales of Staccato® alprazolam. The transaction is expected to close by the end of 2025, subject to certain conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lee's Pharmaceutical Holdings Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42284) on December 09, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2590349843"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590349843\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590349843?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590349843","market":"fut","top_or_hot":-1,"title":"Lee's Pharmaceutical Acquires Staccato One Breath Technology and Global Rights to Alprazolam","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lee's Pharmaceutical Acquires Staccato One Breath Technology and Global Rights to Alprazolam\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lee's Pharmaceutical Holdings Limited is acquiring the Staccato® One Breath Technology® (OBT®) platform and related assets, including global rights as licensor and manufacturer for Staccato® alprazolam, as part of an expanded partnership with UCB. The Staccato® OBT® platform is a proprietary inhalation technology with applications in central nervous system and neurodegenerative disorders, already validated by the approved product Adasuve® and several late-stage development programs. This transaction will also integrate two Phase 2 clinical-stage CNS assets targeting Parkinson's disease and Cyclic Vomiting Syndrome into Lee's Pharm's portfolio. Upon completion, Lee's Pharm and its partner NPI stand to receive up to US$60.5 million in milestone payments, as well as tiered royalties and manufacturing revenue from global sales of Staccato® alprazolam. The transaction is expected to close by the end of 2025, subject to certain conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lee's Pharmaceutical Holdings Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42284) on December 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lee's Pharmaceutical Acquires Staccato One Breath Technology and Global Rights to Alprazolam</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLee's Pharmaceutical Acquires Staccato One Breath Technology and Global Rights to Alprazolam\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-12-09 21:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lee's Pharmaceutical Acquires Staccato One Breath Technology and Global Rights to Alprazolam\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lee's Pharmaceutical Holdings Limited is acquiring the Staccato® One Breath Technology® (OBT®) platform and related assets, including global rights as licensor and manufacturer for Staccato® alprazolam, as part of an expanded partnership with UCB. The Staccato® OBT® platform is a proprietary inhalation technology with applications in central nervous system and neurodegenerative disorders, already validated by the approved product Adasuve® and several late-stage development programs. This transaction will also integrate two Phase 2 clinical-stage CNS assets targeting Parkinson's disease and Cyclic Vomiting Syndrome into Lee's Pharm's portfolio. Upon completion, Lee's Pharm and its partner NPI stand to receive up to US$60.5 million in milestone payments, as well as tiered royalties and manufacturing revenue from global sales of Staccato® alprazolam. The transaction is expected to close by the end of 2025, subject to certain conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lee's Pharmaceutical Holdings Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42284) on December 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL8L61ty:1","article_id":"2590349843","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590349843","pubTimestamp":1765285273,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lee's Pharmaceutical Holdings Limited is acquiring the Staccato One Breath Technology  platform and related assets, including global rights as licensor and manufacturer for Staccato alprazolam, as part of an expanded partnership with UCB. The Staccato OBT platform is a proprietary inhalation technology with applications in central nervous system and neurodegenerative disorders, already validated by the approved product Adasuve and several late-stage development programs. This transaction will also integrate two Phase 2 clinical-stage CNS assets targeting Parkinson's disease and Cyclic Vomiting Syndrome into Lee's Pharm's portfolio. Upon completion, Lee's Pharm and its partner NPI stand to receive up to US$60.5 million in milestone payments, as well as tiered royalties and manufacturing revenue from global sales of Staccato alprazolam. The transaction is expected to close by the end of 2025, subject to certain conditions.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","00950":"李氏大药厂"},"translate_title":"李氏制药收购Staccato One Breath技术及阿普唑仑全球权益","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00950":0.9},"content_text":"Lee's Pharmaceutical Acquires Staccato One Breath Technology and Global Rights to Alprazolam\n    \n\n        Lee's Pharmaceutical Holdings Limited is acquiring the Staccato® One Breath Technology® (OBT®) platform and related assets, including global rights as licensor and manufacturer for Staccato® alprazolam, as part of an expanded partnership with UCB. The Staccato® OBT® platform is a proprietary inhalation technology with applications in central nervous system and neurodegenerative disorders, already validated by the approved product Adasuve® and several late-stage development programs. This transaction will also integrate two Phase 2 clinical-stage CNS assets targeting Parkinson's disease and Cyclic Vomiting Syndrome into Lee's Pharm's portfolio. Upon completion, Lee's Pharm and its partner NPI stand to receive up to US$60.5 million in milestone payments, as well as tiered royalties and manufacturing revenue from global sales of Staccato® alprazolam. The transaction is expected to close by the end of 2025, subject to certain conditions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lee's Pharmaceutical Holdings Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42284) on December 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}